Novel Targets for the Treatment of Melanoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-11-06

AUTHORS

Lara Ambrosi, Shaheer Khan, Richard D. Carvajal, Jessica Yang

ABSTRACT

Purpose of ReviewIn this article, we will briefly review the current treatment landscape for metastatic melanoma and provide a comprehensive update on emerging novel treatment strategies.Recent FindingsOver the past decade, remarkable advances in immunotherapy and targeted therapy have greatly improved outcomes for patients with advanced melanoma. Although a subset of patients is able to achieve durable responses, the majority experience eventual disease progression on existing therapies. Trials evaluating novel combinatorial strategies, checkpoint inhibitors, immune agonists, T cell–based therapies, intratumoral agents, and others are ongoing.SummaryWhile strides have been made in the treatment of advanced melanoma, further research is needed to identify alternative immune and molecular targets in order to overcome resistance and achieve better clinical outcomes. More... »

PAGES

97

References to SciGraph publications

  • 2015-01-15. Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2005-11-13. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity in NATURE IMMUNOLOGY
  • 2017-02-21. Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2017-04-18. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2011-08-28. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido in NATURE MEDICINE
  • 2017-03-01. Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies in CURRENT ONCOLOGY REPORTS
  • 2018-08-21. Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer in MAMMALIAN GENOME
  • 2013-11-07. Extremely potent immunotherapeutic activity of a STING agonist in the B16 melanoma model in vivo in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2018-03-15. Next generation of immune checkpoint therapy in cancer: new developments and challenges in JOURNAL OF HEMATOLOGY & ONCOLOGY
  • 2002-01. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease in NATURE
  • 2014-02-15. ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2019-01-15. Immunotherapy Bridge 2018 and Melanoma Bridge 2018: meeting abstracts in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2018-06-18. Targeting adenosine for cancer immunotherapy in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2006-01. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer in NATURE REVIEWS CANCER
  • 2012-04-19. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours in BRITISH JOURNAL OF CANCER
  • 2015-03-31. The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial in BRITISH JOURNAL OF CANCER
  • 2017-07-05. An immunogenic personal neoantigen vaccine for patients with melanoma in NATURE
  • 2014-10-28. Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma in ANNALS OF SURGICAL ONCOLOGY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s11912-019-0849-4

    DOI

    http://dx.doi.org/10.1007/s11912-019-0849-4

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1122361547

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/31696329


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Agents, Immunological", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Biomarkers, Tumor", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Resistance, Neoplasm", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunologic Factors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunotherapy", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Melanoma", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Molecular Targeted Therapy", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tumor Microenvironment", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Stony Brook SOM, 101 Nicholls Rd, 11794, Stony Brook, NY, USA", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Stony Brook SOM, 101 Nicholls Rd, 11794, Stony Brook, NY, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ambrosi", 
            "givenName": "Lara", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Hematology/Oncology, Columbia University Medical Center, 177 Fort Washington Ave, MHB 6GN-435, 10032, New York, NY, USA", 
              "id": "http://www.grid.ac/institutes/grid.239585.0", 
              "name": [
                "Division of Hematology/Oncology, Columbia University Medical Center, 177 Fort Washington Ave, MHB 6GN-435, 10032, New York, NY, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Khan", 
            "givenName": "Shaheer", 
            "id": "sg:person.016242444426.32", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016242444426.32"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Hematology/Oncology, Columbia University Medical Center, 177 Fort Washington Ave, MHB 6GN-435, 10032, New York, NY, USA", 
              "id": "http://www.grid.ac/institutes/grid.239585.0", 
              "name": [
                "Division of Hematology/Oncology, Columbia University Medical Center, 177 Fort Washington Ave, MHB 6GN-435, 10032, New York, NY, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Carvajal", 
            "givenName": "Richard D.", 
            "id": "sg:person.0726366600.25", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Hematology/Oncology, Columbia University Medical Center, 177 Fort Washington Ave, MHB 6GN-435, 10032, New York, NY, USA", 
              "id": "http://www.grid.ac/institutes/grid.239585.0", 
              "name": [
                "Division of Hematology/Oncology, Columbia University Medical Center, 177 Fort Washington Ave, MHB 6GN-435, 10032, New York, NY, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Yang", 
            "givenName": "Jessica", 
            "id": "sg:person.012452126060.89", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012452126060.89"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/s00262-014-1525-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023054548", 
              "https://doi.org/10.1007/s00262-014-1525-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s40425-018-0360-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1104903069", 
              "https://doi.org/10.1186/s40425-018-0360-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ni1271", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010092554", 
              "https://doi.org/10.1038/ni1271"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s11912-017-0579-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1084033425", 
              "https://doi.org/10.1007/s11912-017-0579-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/2051-1426-1-s1-o15", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1053150873", 
              "https://doi.org/10.1186/2051-1426-1-s1-o15"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bjc.2012.154", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031103423", 
              "https://doi.org/10.1038/bjc.2012.154"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00335-018-9770-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1106272152", 
              "https://doi.org/10.1007/s00335-018-9770-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s12967-018-1745-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1111432790", 
              "https://doi.org/10.1186/s12967-018-1745-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13045-018-0582-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1101542748", 
              "https://doi.org/10.1186/s13045-018-0582-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1479-5876-13-s1-o6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1000403701", 
              "https://doi.org/10.1186/1479-5876-13-s1-o6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/415536a", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008050393", 
              "https://doi.org/10.1038/415536a"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s40425-017-0220-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1083919340", 
              "https://doi.org/10.1186/s40425-017-0220-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s40425-017-0238-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1084612708", 
              "https://doi.org/10.1186/s40425-017-0238-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc1779", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033300049", 
              "https://doi.org/10.1038/nrc1779"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1245/s10434-014-4169-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009814101", 
              "https://doi.org/10.1245/s10434-014-4169-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bjc.2014.541", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044947829", 
              "https://doi.org/10.1038/bjc.2014.541"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm.2438", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005333082", 
              "https://doi.org/10.1038/nm.2438"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature22991", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1090346424", 
              "https://doi.org/10.1038/nature22991"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2019-11-06", 
        "datePublishedReg": "2019-11-06", 
        "description": "Purpose of ReviewIn this article, we will briefly review the current treatment landscape for metastatic melanoma and provide a comprehensive update on emerging novel treatment strategies.Recent FindingsOver the past decade, remarkable advances in immunotherapy and targeted therapy have greatly improved outcomes for patients with advanced melanoma. Although a subset of patients is able to achieve durable responses, the majority experience eventual disease progression on existing therapies. Trials evaluating novel combinatorial strategies, checkpoint inhibitors, immune agonists, T cell\u2013based therapies, intratumoral agents, and others are ongoing.SummaryWhile strides have been made in the treatment of advanced melanoma, further research is needed to identify alternative immune and molecular targets in order to overcome resistance and achieve better clinical outcomes.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s11912-019-0849-4", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1021174", 
            "issn": [
              "1523-3790", 
              "1534-6269"
            ], 
            "name": "Current Oncology Reports", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "11", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "21"
          }
        ], 
        "keywords": [
          "advanced melanoma", 
          "T cell-based therapies", 
          "eventual disease progression", 
          "current treatment landscape", 
          "subset of patients", 
          "better clinical outcomes", 
          "novel treatment strategies", 
          "treatment of melanoma", 
          "novel combinatorial strategies", 
          "Purpose of ReviewIn", 
          "checkpoint inhibitors", 
          "treatment landscape", 
          "durable responses", 
          "clinical outcomes", 
          "cell-based therapies", 
          "metastatic melanoma", 
          "targeted therapy", 
          "disease progression", 
          "immune agonists", 
          "treatment strategies", 
          "melanoma", 
          "novel target", 
          "Recent FindingsOver", 
          "therapy", 
          "molecular targets", 
          "comprehensive update", 
          "patients", 
          "combinatorial strategies", 
          "outcomes", 
          "treatment", 
          "further research", 
          "remarkable advances", 
          "immunotherapy", 
          "agonists", 
          "progression", 
          "trials", 
          "ReviewIn", 
          "target", 
          "inhibitors", 
          "past decade", 
          "majority", 
          "agents", 
          "subset", 
          "response", 
          "strategies", 
          "update", 
          "resistance", 
          "strides", 
          "advances", 
          "purpose", 
          "decades", 
          "research", 
          "article", 
          "order", 
          "landscape"
        ], 
        "name": "Novel Targets for the Treatment of Melanoma", 
        "pagination": "97", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1122361547"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s11912-019-0849-4"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "31696329"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s11912-019-0849-4", 
          "https://app.dimensions.ai/details/publication/pub.1122361547"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-12-01T06:39", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_802.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s11912-019-0849-4"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11912-019-0849-4'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11912-019-0849-4'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11912-019-0849-4'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11912-019-0849-4'


     

    This table displays all metadata directly associated to this object as RDF triples.

    247 TRIPLES      21 PREDICATES      106 URIs      80 LITERALS      16 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s11912-019-0849-4 schema:about N2397212567a54ab7b4feadb824e6b397
    2 N36d23f8605e246eabfa4aa09a3091984
    3 N540e10100bf1441ebe912abcd31caf53
    4 N7005852f53b64444b1f2352ecca026db
    5 N727d8434e6954c959a528331ad87d0d4
    6 N8ff54716e2034fbf9ea9b435fc95e24b
    7 Ne69a89e00f934adead21e60a01e19b2b
    8 Ne92c6c0a71e44885ac99b6d7a1c8986b
    9 Nf5a29d8c19364e70bc96fec9ef794a4a
    10 anzsrc-for:11
    11 anzsrc-for:1112
    12 schema:author Nfc298f67e7d24c169ea02af00b4f4906
    13 schema:citation sg:pub.10.1007/s00262-014-1525-z
    14 sg:pub.10.1007/s00335-018-9770-7
    15 sg:pub.10.1007/s11912-017-0579-4
    16 sg:pub.10.1038/415536a
    17 sg:pub.10.1038/bjc.2012.154
    18 sg:pub.10.1038/bjc.2014.541
    19 sg:pub.10.1038/nature22991
    20 sg:pub.10.1038/ni1271
    21 sg:pub.10.1038/nm.2438
    22 sg:pub.10.1038/nrc1779
    23 sg:pub.10.1186/1479-5876-13-s1-o6
    24 sg:pub.10.1186/2051-1426-1-s1-o15
    25 sg:pub.10.1186/s12967-018-1745-7
    26 sg:pub.10.1186/s13045-018-0582-8
    27 sg:pub.10.1186/s40425-017-0220-y
    28 sg:pub.10.1186/s40425-017-0238-1
    29 sg:pub.10.1186/s40425-018-0360-8
    30 sg:pub.10.1245/s10434-014-4169-5
    31 schema:datePublished 2019-11-06
    32 schema:datePublishedReg 2019-11-06
    33 schema:description Purpose of ReviewIn this article, we will briefly review the current treatment landscape for metastatic melanoma and provide a comprehensive update on emerging novel treatment strategies.Recent FindingsOver the past decade, remarkable advances in immunotherapy and targeted therapy have greatly improved outcomes for patients with advanced melanoma. Although a subset of patients is able to achieve durable responses, the majority experience eventual disease progression on existing therapies. Trials evaluating novel combinatorial strategies, checkpoint inhibitors, immune agonists, T cell–based therapies, intratumoral agents, and others are ongoing.SummaryWhile strides have been made in the treatment of advanced melanoma, further research is needed to identify alternative immune and molecular targets in order to overcome resistance and achieve better clinical outcomes.
    34 schema:genre article
    35 schema:isAccessibleForFree false
    36 schema:isPartOf N1de795562989478b8735bd71a8ac677b
    37 N5ac663d3bc144eecbe3afee1fd397700
    38 sg:journal.1021174
    39 schema:keywords Purpose of ReviewIn
    40 Recent FindingsOver
    41 ReviewIn
    42 T cell-based therapies
    43 advanced melanoma
    44 advances
    45 agents
    46 agonists
    47 article
    48 better clinical outcomes
    49 cell-based therapies
    50 checkpoint inhibitors
    51 clinical outcomes
    52 combinatorial strategies
    53 comprehensive update
    54 current treatment landscape
    55 decades
    56 disease progression
    57 durable responses
    58 eventual disease progression
    59 further research
    60 immune agonists
    61 immunotherapy
    62 inhibitors
    63 landscape
    64 majority
    65 melanoma
    66 metastatic melanoma
    67 molecular targets
    68 novel combinatorial strategies
    69 novel target
    70 novel treatment strategies
    71 order
    72 outcomes
    73 past decade
    74 patients
    75 progression
    76 purpose
    77 remarkable advances
    78 research
    79 resistance
    80 response
    81 strategies
    82 strides
    83 subset
    84 subset of patients
    85 target
    86 targeted therapy
    87 therapy
    88 treatment
    89 treatment landscape
    90 treatment of melanoma
    91 treatment strategies
    92 trials
    93 update
    94 schema:name Novel Targets for the Treatment of Melanoma
    95 schema:pagination 97
    96 schema:productId N0032c87c02444c889fbf41beb8a79a79
    97 N1aa96b6ca2a84dbda27286cf585706cb
    98 N7c5f9efd92d540e78da6f0b6fabf9aef
    99 schema:sameAs https://app.dimensions.ai/details/publication/pub.1122361547
    100 https://doi.org/10.1007/s11912-019-0849-4
    101 schema:sdDatePublished 2022-12-01T06:39
    102 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    103 schema:sdPublisher N9e90843f068c42ae862bf516181174c6
    104 schema:url https://doi.org/10.1007/s11912-019-0849-4
    105 sgo:license sg:explorer/license/
    106 sgo:sdDataset articles
    107 rdf:type schema:ScholarlyArticle
    108 N0032c87c02444c889fbf41beb8a79a79 schema:name dimensions_id
    109 schema:value pub.1122361547
    110 rdf:type schema:PropertyValue
    111 N0357e28353c04189bfffb52d9b1ebffb rdf:first sg:person.012452126060.89
    112 rdf:rest rdf:nil
    113 N1aa96b6ca2a84dbda27286cf585706cb schema:name doi
    114 schema:value 10.1007/s11912-019-0849-4
    115 rdf:type schema:PropertyValue
    116 N1de795562989478b8735bd71a8ac677b schema:issueNumber 11
    117 rdf:type schema:PublicationIssue
    118 N2397212567a54ab7b4feadb824e6b397 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    119 schema:name Antineoplastic Agents, Immunological
    120 rdf:type schema:DefinedTerm
    121 N36d23f8605e246eabfa4aa09a3091984 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    122 schema:name Immunotherapy
    123 rdf:type schema:DefinedTerm
    124 N3ebc838e660843e7b3ed8cd57880d868 schema:affiliation grid-institutes:None
    125 schema:familyName Ambrosi
    126 schema:givenName Lara
    127 rdf:type schema:Person
    128 N540e10100bf1441ebe912abcd31caf53 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    129 schema:name Molecular Targeted Therapy
    130 rdf:type schema:DefinedTerm
    131 N5ac663d3bc144eecbe3afee1fd397700 schema:volumeNumber 21
    132 rdf:type schema:PublicationVolume
    133 N6e76e381b5a5436d8872ccf5fc9728f5 rdf:first sg:person.016242444426.32
    134 rdf:rest N8e5b8f93d0c445cb937ff612bde9cf49
    135 N7005852f53b64444b1f2352ecca026db schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    136 schema:name Immunologic Factors
    137 rdf:type schema:DefinedTerm
    138 N727d8434e6954c959a528331ad87d0d4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    139 schema:name Melanoma
    140 rdf:type schema:DefinedTerm
    141 N7c5f9efd92d540e78da6f0b6fabf9aef schema:name pubmed_id
    142 schema:value 31696329
    143 rdf:type schema:PropertyValue
    144 N8e5b8f93d0c445cb937ff612bde9cf49 rdf:first sg:person.0726366600.25
    145 rdf:rest N0357e28353c04189bfffb52d9b1ebffb
    146 N8ff54716e2034fbf9ea9b435fc95e24b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    147 schema:name Drug Resistance, Neoplasm
    148 rdf:type schema:DefinedTerm
    149 N9e90843f068c42ae862bf516181174c6 schema:name Springer Nature - SN SciGraph project
    150 rdf:type schema:Organization
    151 Ne69a89e00f934adead21e60a01e19b2b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    152 schema:name Humans
    153 rdf:type schema:DefinedTerm
    154 Ne92c6c0a71e44885ac99b6d7a1c8986b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    155 schema:name Tumor Microenvironment
    156 rdf:type schema:DefinedTerm
    157 Nf5a29d8c19364e70bc96fec9ef794a4a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    158 schema:name Biomarkers, Tumor
    159 rdf:type schema:DefinedTerm
    160 Nfc298f67e7d24c169ea02af00b4f4906 rdf:first N3ebc838e660843e7b3ed8cd57880d868
    161 rdf:rest N6e76e381b5a5436d8872ccf5fc9728f5
    162 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    163 schema:name Medical and Health Sciences
    164 rdf:type schema:DefinedTerm
    165 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    166 schema:name Oncology and Carcinogenesis
    167 rdf:type schema:DefinedTerm
    168 sg:journal.1021174 schema:issn 1523-3790
    169 1534-6269
    170 schema:name Current Oncology Reports
    171 schema:publisher Springer Nature
    172 rdf:type schema:Periodical
    173 sg:person.012452126060.89 schema:affiliation grid-institutes:grid.239585.0
    174 schema:familyName Yang
    175 schema:givenName Jessica
    176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012452126060.89
    177 rdf:type schema:Person
    178 sg:person.016242444426.32 schema:affiliation grid-institutes:grid.239585.0
    179 schema:familyName Khan
    180 schema:givenName Shaheer
    181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016242444426.32
    182 rdf:type schema:Person
    183 sg:person.0726366600.25 schema:affiliation grid-institutes:grid.239585.0
    184 schema:familyName Carvajal
    185 schema:givenName Richard D.
    186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25
    187 rdf:type schema:Person
    188 sg:pub.10.1007/s00262-014-1525-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1023054548
    189 https://doi.org/10.1007/s00262-014-1525-z
    190 rdf:type schema:CreativeWork
    191 sg:pub.10.1007/s00335-018-9770-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106272152
    192 https://doi.org/10.1007/s00335-018-9770-7
    193 rdf:type schema:CreativeWork
    194 sg:pub.10.1007/s11912-017-0579-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084033425
    195 https://doi.org/10.1007/s11912-017-0579-4
    196 rdf:type schema:CreativeWork
    197 sg:pub.10.1038/415536a schema:sameAs https://app.dimensions.ai/details/publication/pub.1008050393
    198 https://doi.org/10.1038/415536a
    199 rdf:type schema:CreativeWork
    200 sg:pub.10.1038/bjc.2012.154 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031103423
    201 https://doi.org/10.1038/bjc.2012.154
    202 rdf:type schema:CreativeWork
    203 sg:pub.10.1038/bjc.2014.541 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044947829
    204 https://doi.org/10.1038/bjc.2014.541
    205 rdf:type schema:CreativeWork
    206 sg:pub.10.1038/nature22991 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090346424
    207 https://doi.org/10.1038/nature22991
    208 rdf:type schema:CreativeWork
    209 sg:pub.10.1038/ni1271 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010092554
    210 https://doi.org/10.1038/ni1271
    211 rdf:type schema:CreativeWork
    212 sg:pub.10.1038/nm.2438 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005333082
    213 https://doi.org/10.1038/nm.2438
    214 rdf:type schema:CreativeWork
    215 sg:pub.10.1038/nrc1779 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033300049
    216 https://doi.org/10.1038/nrc1779
    217 rdf:type schema:CreativeWork
    218 sg:pub.10.1186/1479-5876-13-s1-o6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000403701
    219 https://doi.org/10.1186/1479-5876-13-s1-o6
    220 rdf:type schema:CreativeWork
    221 sg:pub.10.1186/2051-1426-1-s1-o15 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053150873
    222 https://doi.org/10.1186/2051-1426-1-s1-o15
    223 rdf:type schema:CreativeWork
    224 sg:pub.10.1186/s12967-018-1745-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111432790
    225 https://doi.org/10.1186/s12967-018-1745-7
    226 rdf:type schema:CreativeWork
    227 sg:pub.10.1186/s13045-018-0582-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101542748
    228 https://doi.org/10.1186/s13045-018-0582-8
    229 rdf:type schema:CreativeWork
    230 sg:pub.10.1186/s40425-017-0220-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1083919340
    231 https://doi.org/10.1186/s40425-017-0220-y
    232 rdf:type schema:CreativeWork
    233 sg:pub.10.1186/s40425-017-0238-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084612708
    234 https://doi.org/10.1186/s40425-017-0238-1
    235 rdf:type schema:CreativeWork
    236 sg:pub.10.1186/s40425-018-0360-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104903069
    237 https://doi.org/10.1186/s40425-018-0360-8
    238 rdf:type schema:CreativeWork
    239 sg:pub.10.1245/s10434-014-4169-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009814101
    240 https://doi.org/10.1245/s10434-014-4169-5
    241 rdf:type schema:CreativeWork
    242 grid-institutes:None schema:alternateName Stony Brook SOM, 101 Nicholls Rd, 11794, Stony Brook, NY, USA
    243 schema:name Stony Brook SOM, 101 Nicholls Rd, 11794, Stony Brook, NY, USA
    244 rdf:type schema:Organization
    245 grid-institutes:grid.239585.0 schema:alternateName Division of Hematology/Oncology, Columbia University Medical Center, 177 Fort Washington Ave, MHB 6GN-435, 10032, New York, NY, USA
    246 schema:name Division of Hematology/Oncology, Columbia University Medical Center, 177 Fort Washington Ave, MHB 6GN-435, 10032, New York, NY, USA
    247 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...